Amicus Sees Delay in US Approval Of Drug - Wall Street Journal

Amicus Therapeutics Inc. lost more than half its market value Friday after the drug maker said it has delayed plans to seek U.S. approval of its treatment for a rare genetic disorder because of questions from regulators.

The Cranbury, N.J., company was expected to submit a new drug application for its migalastat monotherapy, known as Galafold, by the end of the year to the U.S. Food and Drug Administration. However, Amicus said...

Read Full Story